Press Release  |  July 25, 2022

Thunder Bay, Ontario, Canada – July 25, 2022 – IGY Life Sciences and Immune Technologies Inc. (the “Company” or “IGY Life Sciences”) is pleased to announce it has reached 94.8% purity of Muno-IgYTM, the Company’s branded nutraceutical IgY ingredient for targeting immune and gut health through supplementation of antibodies derived from hen egg yolks.

Independent analytical testing was conducted by Edmonton, Alberta-based Keystone Laboratories using the Company’s proprietary HPLC methodology for measuring IgY proteins. High Performance Liquid Chromatography is the industry standard to measure purity of proteins. IGY Life Sciences supplied the sample directly from their production room, on July 10th.

“The 94.8% purity is the mean from triplicate analysis. This is a major milestone within the industry” explained Dr. Navneet Sharma, Chief of Quality and Regulatory Compliance.

The new milestone moves the production capability from the 30% average purity over the past year to what would be considered a ‘Pharmaceutical Grade’ biologic. This is an important achievement as the industry average for Whole Yolk IgY is 1-3% and that product contains a lot of fat resulting in a shortened shelf-life. The ability to produce antibodies at such prominent levels of purity is a defining advantage of IGY Life Sciences capabilities and the Company’s products.

“Refining our production process to manufacture a higher purity product has been the primary goal for the Company over the past year. We are incredibly pleased with results delivered by our research and development team.” said Terry Dyck, IGY Life Sciences’ CEO. He adds, “For our nutraceutical products, high purity IgY allows our clients to offer a consistent product with a much higher level of efficacy. Our Muno-IgY will be standardized at 50% pure for the nutraceutical industry and move to higher purity levels for specific antibodies used within the pharmaceutical industry. For pharmaceuticals, the new achievement means applications for specific antibodies can now be produced in large scale quantities. Such